Study of AFN50 injection for active lupus
Part of Immune system & allergy clinical trials.
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 69 years old and have a definite diagnosis of lupus (SLE) based on updated guidelines.
- Your lupus has stayed active or come back even though you have been on stable treatment (steroids, antimalarials, or immune-suppressing drugs) for at least 8 weeks.
- You must have tried and not responded well to hydroxychloroquine OR at least two other standard immune-suppressing drugs.
- You need to have blood test results showing lupus-related markers: a positive ANA or anti-dsDNA test, or low complement levels.
- You cannot have certain infections (like hepatitis B, C, HIV, CMV, syphilis), a history of major organ transplant, or certain heart problems.
- You must not be pregnant or breastfeeding and agree to use birth control for 12 months after receiving the injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests a new injection called ACG102 for people with lupus that has not improved with standard treatments. The goal is to see if it can help control active lupus symptoms.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.